How do you decide between radioligand therapy or cytotoxic chemotherapy in patients with metastatic castration-resistant prostate cancer with prior ARPI exposure who have cancer-related anemia?
Given that both carry risks of worsening anemia, and both potentially may help the anemia if disease-related, how do you come up with your decision? How do you provide supportive care throughout the process?
Community PollStarted
What is your preferred treat in patients with metastatic castration-resistant prostate cancer with prior ARPI exposure who have cancer-related anemia?
16 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Northwestern University
Answered on
Radioligand therapy (presumably the question refers to Lu-177 vipivotide tetraxaten/Pluvicto) is one of the latest and most promising treatments for mCRPC. As in all cancer treatments, the practitioner needs to have a good understanding of adverse event likelihood, but also the potential for benefit...
Join for free or sign in to see the full answer